Log In
Print this Print this

Emselex, Enablex, darifenacin

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionMuscarinic acetylcholine receptor M3 antagonist
Molecular Target Muscarinic acetylcholine receptor M3 (CHRM3) (HM3)
Mechanism of ActionMuscarinic acetylcholine receptor M3 antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsEffect of overactive bladder (OAB) treatment on memory function; Treat overactive bladder (OAB)
Regulatory Designation


Actavis plc; Merus Labs International Inc.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today